admin

admin

PureTech studies optimistic LYT-200 trial ends in AML/MDS

SAN DIEGO – PureTech Well being plc (NASDAQ:PRTC, LSE:PRTC) shared promising information from a Section 1b trial of LYT-200, a novel anti-galectin-9 monoclonal antibody, on the American Society of Hematology (ASH) Annual Assembly. The trial concerned sufferers with relapsed or…